...indicate Lilly’s tirzepatide bests Novo’s semaglutide on multiple efficacy metrics for Type II diabetes, but saw...

...of public biotechs valued at more than $1 billion since the beginning of 2020, Pandion saw...

...with exits driving fund size increases that saw...

...small part of what the company is working on.Of syndicates and SoftbankThe series C round saw...

...of clinical CAR T data that also saw...
...mode of antigen escape they identified: both saw...

...round it raised in March 2020. CAM Capital and Polaris Partners led Primmune’s A round, which saw...

...HIV infection is expected to start this year.GreatPoint Ventures led Wednesday’s funding round, which also saw...

...capital from institutional LPs to invest in biotech. The once star of British biotech fundraising saw...

...Thursday, Merck reported $48 billion in total 2020 sales, including $14.4 billion from Keytruda, which saw...

...proof of concept for the platform, Gilead saw...